Article info
PDFOriginal research
CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer
- Correspondence to Dr Ingrid Boere, Cancer Institute Department of Medical Oncology, Erasmus MC, Rotterdam, Zuid-Holland, The Netherlands; i.boere{at}erasmusmc.nl
Citation
CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer
Publication history
- Received January 22, 2023
- Accepted April 6, 2023
- First published April 17, 2023.
Online issue publication
October 18, 2023
Article Versions
- Previous version (7 August 2023).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.